Janney Montgomery Scott LLC Purchases 2,836 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Janney Montgomery Scott LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 43.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,339 shares of the biopharmaceutical company’s stock after acquiring an additional 2,836 shares during the period. Janney Montgomery Scott LLC’s holdings in Alnylam Pharmaceuticals were worth $3,090,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ALNY. Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares during the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $895,816,000. Arrowstreet Capital Limited Partnership raised its position in shares of Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $369,943,000. Finally, AQR Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after purchasing an additional 555,759 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 2.7%

NASDAQ ALNY opened at $321.59 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $273.11 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $42.94 billion, a PE ratio of 87.87 and a beta of 0.27. The company has a fifty day moving average of $295.81 and a 200 day moving average of $326.82.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.44) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ALNY shares. Jefferies Financial Group restated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. HC Wainwright lowered their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating for the company in a research note on Monday, June 29th. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Citigroup began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price on the stock. Finally, Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $461.39.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.